Mistral Pharma Inc.

Mistral Pharma Inc.

April 25, 2007 15:30 ET

Mistral Pharma Gives Update on Pipeline Products

MONTREAL, QUEBEC--(CCNMatthews - April 25, 2007) - Mistral Pharma Inc. (TSX VENTURE:MIP) ("Mistral") updated investors today on its product pipeline during the BioFinance conference in Toronto. Mr. Bertrand Bolduc, President & CEO of Mistral stated: "The last year has been quite positive for Mistral and its pipeline products have progressed well. We have entered into exclusive discussions with a strategic partner for MIST-B01 for the co-development and commercialization of our product for the US market. We hope to conclude a definitive agreement in the coming months. MIST-B02 has showed positive results in its first pilot study. Mistral is initiating discussions with potential development partners. MIST-B03 will be the subject of a first pilot PK trial in the third and fourth quarters of 2007. If the results are positive, business development activities will also be initiated for MIST-B03" he concluded.

MIST-B01, Mistral's first branded product, is a controlled-delivery formulation of a widely prescribed drug, which is already approved around the world for numerous treatments including dermatology indications. According to Drug Topics, annual sales of the molecule targeted by MIST-B01 surpassed US $ 200 M. MIST-B02 is a controlled-release version of a drug in the gastroenterology field which is marketed in most European markets, Canada and some Asian countries. MIST-B02 would be a new chemical entity in the US. MIST-B03 is a combination product which would be indicated for inflammatory diseases.

About Mistral Pharma Inc.

Mistral Pharma is a pharmaceutical product development and drug delivery company and its first two branded products, MIST-B01 & B02, showed positive results at their respective first pilot clinical trials. Mistral is also working on other control-delivery branded products. Mistral positions itself as a development partner for specialty pharmaceutical companies. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President & Chief Executive Officer
    514-421-1717 # 2224
    Mistral Pharma Inc.
    Alain Provencher, CA, CF
    Vice-president, Finance & Chief Financial Officer
    514-421-1717 # 2222